DOST explains why PH Ivermectin clinical trial has not yet s

The Department of Science and Technology (DOST) has explained why the country’s eight month-long clinical trial seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug Ivermectin in asymptomatic and mild coronavirus disease (COVID-19) patients confined in isolati

Related Keywords

University Of The Philippines , Quezon City , Philippines , Diliman , Bulacan , Manila , Metro Manila , Philippines General , Filipino , Rowena Cristinal Guevara , Aileen Wang , Manila College Of Pharmacy , Undersecretary For Research , National Institute Of Health , Drug Administration , University Of The Philippines Diliman , Single Joint Research Ethics Board , Department Of Science , Development Dr , Makati Science High School Quarantine Facility , Rowena Cristina , Philippines National Institute , Philippines Manila Research Ethics Board , Philippines Philippine General Hospital , Data Trial Management System , Ateneo Quarantine Facility , Philippines Diliman , Makati Science High School Quarantine ,